Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 216,197 shares of the medical equipment provider’s stock after buying an additional 7,923 shares during the period. Sequoia Financial Advisors LLC owned 0.11% of Zimmer Biomet worth $23,338,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Kempner Capital Management Inc. bought a new position in Zimmer Biomet in the 3rd quarter valued at about $2,834,000. Border to Coast Pensions Partnership Ltd boosted its position in shares of Zimmer Biomet by 4.5% during the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock valued at $16,711,000 after purchasing an additional 6,623 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Zimmer Biomet by 0.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider’s stock valued at $277,357,000 after purchasing an additional 9,990 shares in the last quarter. ST Germain D J Co. Inc. boosted its position in shares of Zimmer Biomet by 4.6% during the 3rd quarter. ST Germain D J Co. Inc. now owns 95,730 shares of the medical equipment provider’s stock valued at $10,334,000 after purchasing an additional 4,218 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in shares of Zimmer Biomet by 165.3% during the 3rd quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock valued at $187,000 after purchasing an additional 1,071 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. BTIG Research reduced their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Oppenheimer decreased their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Robert W. Baird decreased their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Evercore ISI decreased their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Finally, Truist Financial reiterated a “hold” rating and issued a $112.00 target price (down from $117.00) on shares of Zimmer Biomet in a report on Friday, September 13th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $123.94.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded down $1.15 during midday trading on Tuesday, hitting $104.05. The company had a trading volume of 279,550 shares, compared to its average volume of 1,476,304. The business’s 50 day simple moving average is $108.07 and its two-hundred day simple moving average is $112.03. The stock has a market cap of $21.41 billion, a PE ratio of 22.77, a P/E/G ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the previous year, the company earned $1.82 earnings per share. The business’s revenue was up 3.9% compared to the same quarter last year. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.97 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is presently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.